FREMONT, Calif., Feb. 21, 2019 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX) today announced that Mike
Raab, president and chief executive officer of Ardelyx, will
participate in a fireside chat at the Leerink Partners Global
Healthcare Conference at 2:30 p.m. ET on
Thursday, Feb. 28, 2019 at the Lotte New York Palace Hotel
in New York City.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the conference.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the way people with cardiorenal diseases are treated by developing
first-in-class medicines. Ardelyx's cardiorenal pipeline includes
the Phase 3 development of tenapanor for the treatment of
hyperphosphatemia in people with end-stage renal disease (ESRD) who
are on dialysis, and RDX013, a potassium secretagogue program for
the potential treatment of high potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease. In
addition, Ardelyx has completed Phase 3 development of tenapanor
for the treatment of irritable bowel syndrome with constipation
(IBS-C) and submitted a new drug application, or NDA, to the U.S.
Food and Drug Administration, or FDA, for the treatment of patients
with IBS-C which has been granted a target action date under the
Prescription Drug User Fee Act (PDUFA) of September 12, 2019. To efficiently bring its
treatments to market, Ardelyx is pursuing strategic collaborations
for tenapanor for IBS-C and hyperphosphatemia in certain
territories. Ardelyx has established agreements with Kyowa Hakko
Kirin in Japan, Fosun Pharma in
China and Knight Therapeutics in
Canada. For more information,
please visit http://www.ardelyx.com/ and connect with us on Twitter
@Ardelyx.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-participate-in-leerink-partners-8th-annual-global-healthcare-conference-300799410.html
SOURCE Ardelyx